Diagnosis and definition of treatment-resistant depression

Biological Psychiatry

Volumn 53, Issue 8, 2003, Pages 649-659

  Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Definition; Depression; Diagnosis; Resistance; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT;

CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; ELECTROCONVULSIVE THERAPY; EMPIRICISM; HUMAN; INSTRUMENTATION; META ANALYSIS; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; REVIEW; STANDARDIZATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; DRUG RESISTANCE; MAJOR DEPRESSION; NOMENCLATURE; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; HUMANS; PSYCHOTHERAPY; TERMINOLOGY;

EID: 0038147546     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00231-2     Document Type: Review

References (74)

1. Baer L, Jacobs DG, Meszler-Reizes J, Biais M, Fava M, Kessler R, et al (2000): Development of a brief screening instrument: The HANDS. Psychother Psychosom 69:35-41.
2. Bakish D (2001): New standard of depression treatment: Remission and full recovery. J Clin Psychiatry 62(Suppl 26):5-9.
3. Beck AT, Steer RA (1984): Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 40:1365-1367.
4. Bosworth HB, Hays JC, George LK, Steffens DC (2002): Psychosocial and clinical predictors of unipolar depression outcome in older adults. Int J Geriatr Psychiatry 17:238-246.
5. Bowden CL (2001): Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 52:51-55.
6. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR (1996): Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 153:1293-1300.
7. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M (2001): Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 64:261-265.
8. Burrows GD, Norman TR, Judd FK (1994): Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 9(Suppl 2):5-10.
9. Coryell W, Endicott J, Keller M (1990): Outcome of patients with chronic affective disorder: A five-year follow-up. Am J Psychiatry 147:1627-1633.
10. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D (2002): Achieving remission with venlafaxine and fluoxetine in major depression: Its relationship to anxiety symptoms. Depress Anxiety 16:4-13.
11. th Annual Meeting of the American Psychiatric Association, Philadelphia, PA.
12. Fava GA, Savron G, Grandi S, Rafanelli C (1997): Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 58:278-282.
13. Fava M, Davidson KG (1996): Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
14. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, et al (2001): Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. J Clin Psychiatry 62:413-420.
15. Fava M, Kaji J (1994): Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 24:281-290.
16. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF (1997): Major depressive subtypes and treatment response. Biol Psychiatry 42:568-576.
17. Flint AJ, Rifat SL (1997): Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry 5:107-115.
18. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al (1991): Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.
19. Frank E, Shear MK, Rucci P, Cyranowski JM, Endicott J, Fagiolini A, et al (2000): Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 157:1101-1107.
20. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF (2000): Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current "next-step" practices. J Clin Psychiatry 61:403-408.
21. Friedman RA, Parides M, Baff R, Moran M, Kocsis JH (1995): Predictors of response to desipramine in dysthymia. J Clin Psychopharmacol 15:280-283.
22. Glassman AH, Kantor SJ, Shostak M (1975): Depression, delusions, and drug response. Am J Psychiatry 132:716-719.
23. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
24. Hirschfeld RM, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, et al (1998): Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 59:669-675.
25. Jarrett RB, Rush AJ (1994): Short-term psychotherapy of depressive disorders: Current status and future directions. Psychiatry 57:115-132.
26. Joyce PR, Paykel ES (1989): Predictors of drug response in depression. Arch Gen Psychiatry 46:89-99.
27. Joyce PR, Mulder RT, Cloninger CR (1994): Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord 30:35-46.
28. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, et al (2002): Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 36:384-391.
29. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al (1998): Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50:97-108.
30. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB (1991): 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 148:345-350.
31. Kellner R (1987): A symptom questionnaire. J Clin Psychiatry 48:268-274.
32. Kraus RP, Diaz P, McEachran A (1996-1997) Managing rapid metabolizers of antidepressants. Depress Anxiety ;4:320-327.
33. Mace S, Taylor D (2000): Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression. Expert Opin Pharmacother 1:917-933.
34. Miller MD, Lenze EJ, Dew MA, Whyte E, Weber E, Begley AE, et al (2002): Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry 10:592-598.
35. Montgomery SA, Asberg M (1979): A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
36. Mynors-Wallis L, Gath D (1997): Predictors of treatment outcome for major depression in primary care. Psychol Med 27:731-736.
37. Nelson E, Cloninger CR (1997): Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study. J Affect Disord 44:197-200.
38. Newman JR, Ewing SE, McColl RD, Borus JS, Nierenberg AA, Pava J, et al (2000): Tridimensional personality questionnaire and treatment response in major depressive disorder: A negative study. J Affect Disord 57:241-247.
39. Nierenberg AA, Alpert JE (2000): Depressive breakthrough. Psychiatr Clin North Am 23:731-742.
40. Nierenberg AA, Amsterdam JD (1990): Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 51(Suppl):39-47.
41. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994): Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14:419-423.
42. Nierenberg AA, Keck P, Samson J, Rothschild AJ, Schatzberg AF (1991): Methodological considerations for the study of treatment-resistant depression. In: Amsterdam JD, editor. Refractory Depression. New York: Raven Press, 1-12.
43. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M (1995): Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-3.
44. Oslin DW, Datto CJ, Kallan MJ, Katz IR, Edell WS, TenHave T (2002): Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc 50:823-828.
45. Papakostas GI, Petersen T, Iosifescu DV, Roffi P, Alpert JE, Rosenbaum JF, et al (in press b): Axis III co-morbidity in treatment-resistant depression. Psychiatry Research.
46. Papakostas GI, Petersen T, Mischoulon D, Alpert JE, Fava M, Nierenberg AA (in press a): Functioning and interpersonal relationships as predictors of response in treatment resistant depression. Comprehensive Psychiatry.
47. Paykel ES (2002): Achieving gains beyond response. Acta Psychiatr Scand 415(suppl): 12-17.
48. Petersen T, Gordon JA, Kant A, Fava M, Rosenbaum JF, Nierenberg. Treatment resistant depression and axis I comorbidity. Psychol Med 2001;31:1223-1229.
49. Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, et al (2002b): Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom 71:269-274.
50. Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, et al (2002a): NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res 109:9-16.
51. Poirier MF, Boyer P (1999): Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 175:12-16.
52. Quitkin FM, Rabkin JG, Stewart JW, McGrath PJ, Harrison W (1986): Study duration in antidepressant research: Advantages of a 12-week trial. J Psychiatr Res 20:211-216.
53. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, et al (1993): Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 21(Suppl):30-34.
54. Rao ML, Deister A, Laux G, Staberock U, Hoflich G, Moller HJ (1996): Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 29:97-102.
55. Reich JH (1990): Effect of DSM-III personality disorders on outcome of tricyclic antidepressant-treated nonpsychotic out-patients with major or minor depressive disorder. Psychiatry Res 32:175-181.
56. Rigal JG, Albin HC, Duchier AR, D'Aulnay JM, Fenelon JH, Vincon GA, et al (1987): Imipramine blood levels and clinical outcome. J Clin Psychopharmacol 7:222-229.
57. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996): The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 26:477-486.
58. Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, et al (2001): Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13:18-27.
59. Sackeim HA (2001): The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):10-17.
60. Sato T, Hirano S, Narita T, Kusunoki K, Kato J, Goto M, et al (1999): Temperament and character inventory dimensions as a predictor of response to antidepressant treatment in major depression. J Affect Disord 56:153-161.
61. Schatzberg AF, Rothschild AJ (1992): Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 149:733-745.
62. Shea MT, Pilkonis PA, Beckham E, Collins JF, Elkin I, Sotsky SM, et al (1990): Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 147:711-718.
63. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, et al (2002): Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 43:310-316.
64. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al (1999): Treatment resistant depression: Methodological overview and operational criteria. Eur Neuropsychopharmacol 9:83-91.
65. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al (1985): The pharmacological treatment of delusional depression. Am J Psychiatry 142:430-436.
66. Stek ML, Van Exel E, Van Tilburg W, Westendorp RG, Beekman AT (2002): The prognosis of depression in old age: Outcome six to eight years after clinical treatment. Aging Ment Health 6:282-285.
67. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S, et al (1989): Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 46:1080-1087.
68. Thase ME, Friedman ES, Howland RH (2001a): Management of treatment-resistant depression: Psychotherapeutic perspectives. J Clin Psychiatry 62(Suppl 18):18-24.
69. th Annual Meeting of the American Psychiatric Association. New Orleans, LA.
70. Thase ME, Rush AJ (1997): When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23-29.
71. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al (2002): Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59:233-239.
72. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG (1998): Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 28:731-735.
73. Vormfelde SV, Bitsch A, Meineke I, Gundert-Remy UM, Gleiter CH (1997): Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? Eur J Clin Pharmacol 52:387-390.
74. Worthington J, Fava M, Agustin C, Alpert J, Nierenberg AA, Pava JA, et al (1996): Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics 37:518-522.